Hormone therapy, cardio-metabolic profile, and cardiotoxicity. Still a dark side of cardio-oncology - Part 2 : Prostate cancer
Hormone therapies (HTs) with anti-androgenic properties are a cornerstone for the treatment of prostate cancer (PC) and have significantly improved the survival of patients, though exposing them to a higher risk of cardiovascular diseases (CVDs), which represent a major cause of morbidity and mortality. This occurs due to the high average age of patients undergoing HT for PC, an age group in which CVDs have a high prevalence and incidence, and due to the type and duration of HTs that are increasingly effective but at the same time more aggressive towards cardiovascular health. Recent evidence from the real world suggests, however, that the cardiometabolic risk is widely underestimated and undertreated with significant impact also on the oncological prognosis. In the light of the results of the PRONOUNCE study, in this review it is emphasized the need for a multidisciplinary management of patients with PC who are candidate for or treated with HT by implementing a personalized treatment program in accordance with the current European guidelines on CVD prevention.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
Giornale italiano di cardiologia (2006) - 24(2023), 10 vom: 28. Okt., Seite 781-791 |
| Sprache: |
Italienisch |
|---|
| Weiterer Titel: |
Terapia ormonale, assetto cardio-metabolico e cardiotossicità. Il lato ancora oscuro della cardioncologia – Parte 2: Tumore della prostata |
|---|
| Beteiligte Personen: |
Tarantini, Luigi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antineoplastic Agents |
|---|
| Anmerkungen: |
Date Completed 23.10.2023 Date Revised 23.10.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1714/4100.40978 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362640947 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362640947 | ||
| 003 | DE-627 | ||
| 005 | 20231226091646.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||ita c | ||
| 024 | 7 | |a 10.1714/4100.40978 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1208.xml |
| 035 | |a (DE-627)NLM362640947 | ||
| 035 | |a (NLM)37767830 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a ita | ||
| 100 | 1 | |a Tarantini, Luigi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Hormone therapy, cardio-metabolic profile, and cardiotoxicity. Still a dark side of cardio-oncology - Part 2 |b Prostate cancer |
| 246 | 3 | 3 | |a Terapia ormonale, assetto cardio-metabolico e cardiotossicità. Il lato ancora oscuro della cardioncologia – Parte 2: Tumore della prostata |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.10.2023 | ||
| 500 | |a Date Revised 23.10.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Hormone therapies (HTs) with anti-androgenic properties are a cornerstone for the treatment of prostate cancer (PC) and have significantly improved the survival of patients, though exposing them to a higher risk of cardiovascular diseases (CVDs), which represent a major cause of morbidity and mortality. This occurs due to the high average age of patients undergoing HT for PC, an age group in which CVDs have a high prevalence and incidence, and due to the type and duration of HTs that are increasingly effective but at the same time more aggressive towards cardiovascular health. Recent evidence from the real world suggests, however, that the cardiometabolic risk is widely underestimated and undertreated with significant impact also on the oncological prognosis. In the light of the results of the PRONOUNCE study, in this review it is emphasized the need for a multidisciplinary management of patients with PC who are candidate for or treated with HT by implementing a personalized treatment program in accordance with the current European guidelines on CVD prevention | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Hormones |2 NLM | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 700 | 1 | |a Di Girolamo, Stefania |e verfasserin |4 aut | |
| 700 | 1 | |a Masini, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Cioffi, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a Foglietta, Jennifer |e verfasserin |4 aut | |
| 700 | 1 | |a Bracarda, Sergio |e verfasserin |4 aut | |
| 700 | 1 | |a Pinto, Carmine |e verfasserin |4 aut | |
| 700 | 1 | |a Navazio, Alessandro |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Giornale italiano di cardiologia (2006) |d 2006 |g 24(2023), 10 vom: 28. Okt., Seite 781-791 |w (DE-627)NLM16119561X |x 1972-6481 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2023 |g number:10 |g day:28 |g month:10 |g pages:781-791 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1714/4100.40978 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2023 |e 10 |b 28 |c 10 |h 781-791 | ||